Retatrutide - 20mg

What's Included

RT-20 | 20mg Retatrutide vial – bacteriostatic water required (sold separately)

The Advanced Triple Agonist for Metabolic Research

Retatrutide (LY3437943), developed by Eli Lilly, represents the next evolution in peptide-based metabolic therapy research. As a triple-receptor agonist, Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously — offering a broader metabolic response than semaglutide or tirzepatide.

RESEARCH HIGHLIGHTS

Significant Weight Reduction

Promotes marked body mass reductions through enhanced lipolysis and thermogenesis. Phase 2 trials showed up to 24.2% average weight loss over 48 weeks.

Enhanced Satiety Control

Modulates hypothalamic pathways and delays gastric emptying, reducing appetite and prolonging fullness for sustained caloric control.

Superior Glycaemic Management

Stimulates glucose-dependent insulin secretion, suppresses glucagon, and improves HbA1c levels — demonstrating superior outcomes compared with single-pathway agonists.

Comprehensive Metabolic Benefits

Research indicates positive effects on lipid profiles, insulin sensitivity, and hepatic fat content.

COMPARISON

Semaglutide: GLP-1 only | Weight Loss ~15% | Glycaemic control

Tirzepatide: GLP-1 + GIP | Weight Loss ~20% | Glycaemic + insulinotropic

Retatrutide: GLP-1 + GIP + Glucagon | Weight Loss up to 24.2% | Glycaemic + lipolytic + thermogenic

The inclusion of glucagon receptor activation allows Retatrutide to couple catabolic fat-burning with anabolic glucose regulation.

EMERGING RESEARCH

Preliminary data suggest potential applications in PCOS, metabolic liver disease, and cardiometabolic dysfunction studies (pending further validation).

FOR RESEARCH USE ONLY

Retatrutide (LY3437943) is supplied for laboratory and research purposes only. Not intended for human consumption or therapeutic use.